Novasep strengthens its management team with the appointment of Jean-Claude Romain as corporate quality director and Alain Lamproye as director of Novasep Bioproduction sites in Belgium

Novasep strengthens its management team with the appointment of Jean-Claude Romain as corporate quality director and Alain Lamproye as director of Novasep Bioproduction sites in Belgium

Pompey, France, April 23, 2012 - Novasep, a leading supplier of purification and production solutions for the life sciences industry, announces two new managerial appointments. Jean-Claude Romain becomes the group's corporate quality director and a member of Novasep's executive committee, while Alain Lamproye joins Novasep Process, the company's biomolecules division, as director of Novasep Belgium and becomes a member of Novasep Process' management committee.

Jean-Claude Romain brings to the whole Novasep group his experience of quality and industrial production management, which he acquired at several international pharmaceutical companies (including Sanofi-Aventis, Laboratoires Galderma and Johnson & Johnson) and more recently at Novasep Process. His appointment to the newly-created position enables Novasep to establish a global quality management function that will ensure regulatory compliance and contribute to the continuous improvement program for the company's global operations.

Alain Lamproye has held several site management and production management positions at Eurogentec and more recently within the Merck Serono group. He has taken over the management of Novasep's two Belgian sites, which are located south of Brussels. He heads a team of more than 100 staff, that specialize in custom biopharmaceutical manufacturing and are recognized experts in the production of viruses, viral vectors, monoclonal antibodies and recombinant proteins, as well as more recently in the development of innovative compounds such as antibody-drug conjugates (ADCs).

"We are delighted with the appointment of Jean-Claude Romain as corporate quality director of Novasep," said Roger-Marc Nicoud, chairman of Novasep. "His excellent work at Novasep Process has enabled us to continue developing our biopharmaceutical production activities. He is now going to use his experience and dynamism to improve quality control and lead the continuous improvement program at all our sites to ensure we respond to our customers' needs in an ever more effective and reliable fashion."

"The recognized experience of Alain Lamproye represents a real added value for Novasep Belgium," explains Antoine Baule, president of Novasep Process. "In a fast-growing biopharmaceutical market, custom biopharmaceutical manufacturing is a strategic activity for Novasep, which we will actively continue to develop."

About Novasep
Novasep is a global provider of cost-effective and sustainable solutions to produce active molecules at the required purity. Novasep's unique offering includes process development services; purification equipment and turnkey processes; contract manufacturing services and complex active molecules to serve pharmaceutical; biopharmaceutical; agrochemical; fine chemical; food and functional ingredients and white biotechnology industries.

For more information, go to: http://www.novasep.com

Mark Tidmarsh
ANDREW LLOYD & ASSOCIATES
http://www.ala.com
[email protected]

Follow us on Twitter: https://twitter.com/ALA_Group

Brighton Business Centre  95 Ditchling Road  Brighton BN1 4ST  ENGLAND               
Tel:   +44 1273 675100     Fax:  +44 1273 675400

55 rue Boissonade  75014 Paris  FRANCE       
Tel:  +33 1 56 54 07 00     Fax:  +33 1 56 54 07 01

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.